Table 1 β‐blockers used for the treatment of chronic stable angina.
β‐blocker class | Cardio‐selective | Initial dose | Dose range | Unique additional properties | ||
---|---|---|---|---|---|---|
First generation | None | |||||
Propranolol | No | 20 mg twice daily | 40–320 mg twice daily | |||
Timolol | No | 5 mg twice daily | 10–240 mg twice daily | |||
Second generation | None | |||||
Metoprolol | Yes | |||||
Short acting | 25 mg twice daily | 50–200 mg twice daily | ||||
Sustained release | 25 mg daily | 50–200 mg daily | ||||
Atenolol | Yes | 25 mg daily | 25–200 mg daily | |||
Bisoprolol | Yes | 2.5 mg daily | 2.5–20 mg daily | |||
Betaxolol | Yes | 10 mg daily | 10–40 mg daily | |||
Third generation | Vasodilation | |||||
Labetalol | No | 100 mg twice daily | 200–1200 mg twice daily | Higher affinity for α1 receptor (α1 receptor blockade) than β1 and β2 | ||
Carvedilol | Yes | 3.125 mg twice daily | 3.125–25 mg twice daily | β1 selective, ↓selectivity at higher dosesα1 receptor blockade; increases insulin sensitivity; antioxidant properties | ||
Nebivolol | Yes | 2.5 mg daily | 2.5–10 mg daily | Higher β1 selectivity; endothelium‐dependent vasodilation via the L‐arginine/nitric oxide pathway |